dc.contributor.advisor | Suárez Baquero, Alejandra | |
dc.contributor.author | Rugeles Castañeda, Andrea | |
dc.date.accessioned | 2012-05-15T19:16:46Z | |
dc.date.available | 2012-05-15T19:16:46Z | |
dc.date.created | 2007 | |
dc.date.issued | 2012-05-15 | |
dc.identifier.citation | Algado, M.T., et al.(1997). Familia y enfermedad de Alzheimer.Una
perspectiva cualitativa. Anales de Psicología, (13), p.21. | |
dc.identifier.citation | Bartus, RT.(2000) On neurodegenerative diseases, models, and treatment
strategies:lessons learned and lessons forgotten a generation following the
cholinergic hupothesis. Exp Neurol (163). | |
dc.identifier.citation | Bermejo, FP. (1998) La enfermedad de Alzheimer. Medicina Interna (16). | |
dc.identifier.citation | Blasco, I. & Grubeck-Loebenstein, B.(2003). Role of the immune system in
the pathogenesis, prevention and treatment of Alzheimer’s disease. Drugs
Aging.(20).p.105. | |
dc.identifier.citation | Blasco, I. et al.(2004). How chronic inflammation affects the brain and
supports the development of Alzheimer’s disease in old age: the role of
microglia and astrocytes. Aging Cell.(3). | |
dc.identifier.citation | Buffil, E. & Blesa, R. (2006) Alzheimer’s Disease And Brain Evolution: Is
Alzheimer's Disease An Example Of Antagonistic Pleiotropy?. Revista de
Neurología (42).pp.25-26 | |
dc.identifier.citation | Campion, D. et al.(1999). Early-onset autosomal dominant Alzheimer disease:
prevalence,genetic heterogeneity, and mutation spectrum. American Journal
Hum Genet.(65).p.668. | |
dc.identifier.citation | Cruts, M. & Van Broeckhoven, C.(1998).Presenilin mutations in Alzheimer’s
disease.Hum Mutat. (11). | |
dc.identifier.citation | Farrer, LA. et al.(1997). Effects of age, sex, and ethnicity on the association
between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. | |
dc.identifier.citation | APOE and Alzheimer Disease Meta Analysis Consortium. JAMA.(278).p.1350. | |
dc.identifier.citation | Flynn, DD. Et al.(1995). Differential alterations in muscarinic receptor
subtypes in Alzheimer’s disease: implications for cholinergicbased therapies. Life Sci (56).p.86. | |
dc.identifier.citation | Forstl, H. et al. (1992).Clinical and neuropathological correlatesof depression
in Alzheimer’s disease. Psychol Med.(22). | |
dc.identifier.citation | Gálvez, R. et al. (2000) Epidemiología de la enfermedades degenerativas del
sistema nervioso. Barcelona: ed. Masson Salvat-Medicina. | |
dc.identifier.citation | Gómez,T. et al.(1997).Neuronal loss correlates with but exceeds
neurofibrillary tangles in Alzheimer’s disease. Ann Neurol. (41).p.19 | |
dc.identifier.citation | Gottfries, CG. et al.(1995) Neuropeptides and Alzheimer’s disease. Eur
Neuropsychopharmacol.(5). | |
dc.identifier.citation | Hardy, J.et al.(1998).Genetic dissection of Alzheimer’s disease and related
dementias: amyloid and its relationship to tau. Nat Neurosci. (1).p.371.
Hoenicka, J. (2006) Genes In Alzheimer’s Disease.Rev Neurol.(42).pp.302-303 | |
dc.identifier.citation | Huse, JT. & Doms, RW. (2000). Closing in on the amyloid cascade: recent
insights into the cell biology of Alzheimer’s disease. Mol Neurobiol.
(22).p.88. | |
dc.identifier.citation | Ikonomovic, MD.et al.(1999). Distribution of glutamate receptor subunit
NMDAR1 in the hippocampus of normal elderly and patients with
Alzheimer’s disease. Exp Neurol.(160) | |
dc.identifier.citation | Kordower, JH. Et al. (2001). Loss and atrophy of layer II entorhinal cortex
neurons in elderly people with mild cognitive impairment. Ann Neurol (49). | |
dc.identifier.citation | Lanctot, KL. et al (2001) Role of serotonin in the behavioraland psychological
symptoms of dementia. Journal of Neuropsychiat Clinical. (13).p.521. | |
dc.identifier.citation | Lewis, J. et al.(2001) Enhanced neurofibrillary degeneration in transgenic
mice expressing mutant tau and APP. Science. (293). | |
dc.identifier.citation | Li, YM. et al.(2000).Photoactivated gamma-secretase inhibitors directed to the
active site covalently label presenilin 1. Nature.(405) | |
dc.identifier.citation | López, L. & DeKosky, S. (2003). Neuropatología de la enfermedad de
Alzheimer y del deterioro cognitivo leve. Revista Neurologica. (37).p158-159. | |
dc.identifier.citation | Maelicke, A. et al.(2000) Allosterically potentiating ligands of nicotinic
receptors as a treatment strategy for Alzheimer’s disease. Behav Brain Res.
(113). | |
dc.identifier.citation | Martín, CM.et al.(1999). Alpha4 but not Alpha3 and Alpha7 nicotinic
acetylcholine receptor subunits are lost from the temporal cortex in
Alzheimer’s disease. Journal Neurochem. (73). | |
dc.identifier.citation | Martin, JB.(1999). Molecular basis of the neurodegenerative disorders. New
England Journal Med.(340). | |
dc.identifier.citation | Marutle, A, et al.(1999) Neuronal nicotinic receptor deficits in Alzheimer
patients with the Swedish amyloid precursor 670/671 mutation. Journal
Neurochem.(72). | |
dc.identifier.citation | McGeer, EG. & McGeer, PL.(1997). The role of the immune system in
neurodegenerative disorders. Mov Disord.(12). | |
dc.identifier.citation | McGeer, EG. & McGeer, PL.(2003). Inflammatory processes in Alzheimer’s
disease. Prog Neuropsychopharmacol Biol Psychiatry.(27). | |
dc.identifier.citation | Mesulam M. (1995).Structure and function of cholinergic pathways in the
cerebral cortex, limbic system, basal ganglia, and thalamus of the human
brain. New York: Raven Press.p.139. | |
dc.identifier.citation | Mesulam, M. (2000) Principles of behavioral and cognitive neurology.
NewYork: Oxford University Press. | |
dc.identifier.citation | Minton, L. et al.(1997). Somatostatin and neuropeptide Y in cerebrospinal
fluid correlations with severity of disease and clinical signs in Alzheimer’s
disease and frontotemporal dementia. Dement Geriatr Cogn Disord.(8). | |
dc.identifier.citation | Morillo, L. (2006) Alzheimer: ¿Qué es la Enfermedad?. Abc Medicus.
(40).p.4. | |
dc.identifier.citation | Nesse, R. & Williams, G. (1994) Why we get sick. New York: Vintage BooksRandom House. | |
dc.identifier.citation | Nordberg, A. (2001). Nicotonic receptor abnormalities of Alzheimer’s
disease:Therapeutic implications. Biol Psychiatry. (49).p.200. | |
dc.identifier.citation | Nordberg, A. et al. (1998). Longterm tacrine treatment in three mild
Alzheimer patients: Effects on nicotinic receptors, cerebral blood flow, glucose metabolism, EEG and cognitive abilities. Alzheimer Diseas Assoc
Disord. (12). | |
dc.identifier.citation | Paterson,D. & Nordberg, A. (2000). Neural nicotinic receptors in the human
brain. Progress in Neurobiology. (61). | |
dc.identifier.citation | Poirier, J.(1994).Apolipoprotein E in animal models of CNS injury and in
Alzheimer’s disease. Trends Neurosci.(17).p.528. | |
dc.identifier.citation | Price, JL. et al.(2001). Neuron number in the entorhinal cortex and CAI in
preclinical Alzheimer’s disease. Arch Neurol. (58).p.156. | |
dc.identifier.citation | Rogaev, EI. et al.(1995).Familial Alzheimer’s disease in kindreds with
missense mutations in a gene on chromosome 1 related to the Alzheimer’s
disease type 3 gene. Nature. (376). | |
dc.identifier.citation | Schellenberg, GD.et al.(1992).Genetic linkage evidence for a familial
Alzheimer’s disease locus on chromosome 14. Science.(258). | |
dc.identifier.citation | Smith, E. et al. (1999) Evolutionary medicine. New York:Oxford University
Press. p.25 | |
dc.identifier.citation | Strittmatter, WJ.et al.(1993).Apolipoprotein E: high-avidity binding to
betaamyloid and increased frequency of type 4 allele in late-onset failial
Alzheimer disease. Proc Natl Acad Sci.(90).p.197. | |
dc.identifier.citation | Tárraga, L. et al. “Estimulación cognitiva y memoria” Disponible en red:
www.infodoctor.org/alzheimer.htm, extraido el 20 de Abril de 2006}.
Toledo, M. (2006) Inflamación y Enfermedad de Alzheimer. Revista de
Neurología (42).pp.433, 435. | |
dc.identifier.citation | Thomas, M.& Isaac, M. (1987) Alois Alzheimer: a memoir. Trends Neurosci
(10). | |
dc.identifier.citation | Van Broeckhoven, C.et al.(1992). Mapping of a gene predisposing to earlyonset Alzheimer’s disease to chromosome 14q24.3. Nat Genet.(2) | |
dc.identifier.citation | Van Hoesen, GW. & Hyman, BT. (1990) Hippocampal formation: anatomy
and the patterns of patholog Alzheimer’s disease. Brain Res (83).p.448. | |
dc.identifier.citation | Vilalta, J. et al. (2000) Prevalencia de demencias en una zona rural. Revista
Neurológica. (30). | |
dc.identifier.citation | Wilson, RS. et al.(2002). The apolipoprotein E 4 allele and decline in
different cognitive systems during a 6-year period. Arch Neurol.(59). | |
dc.identifier.citation | Zorumski,CF. & Isenberg, KE. (1991) Insights into the structure and function
of GABA benzodiazepine receptors: ion channels and psychiatry. American
Journal of Psychiatry. (148).p.162. | |
dc.identifier.citation | “Neurología, Enfermedad de Alzheimer” Disponible en red
{www.iqb.es/neurologia/enfermedades/alzheimer/enfermedadpaciente/
e003.htm, extraido el 5 de Abril de 2006} | |
dc.identifier.citation | “Historia de una efermedad” Disponible en red {www.
elmundosalud.elmundo.es/elmundosalud/especiales/2004/04/alzheimer/
historia.htm, extraido 10 de Marzo de 2006} | |
dc.identifier.citation | “La enfermedad de Alzheimer, Historia” Disponible en red
{www.grunenthal.es/cw/es_ES/html/cw_es_es_patient.jhtml?CatId=cw
_es_es_patient_d_01b, extraído el 7 de Abril de 2006} | |
dc.identifier.citation | “Stages of Alzheimer's Disease, Alzheimer's Association” Disponible en red
{http://www.alz.org/aboutad/stages.asp, extraido 7 de Abril de 2006} | |
dc.identifier.uri | http://hdl.handle.net/10818/2168 | |
dc.description | 44 Páginas. | |
dc.description.abstract | El Alzheimer es una enfermedad degenerativa progresiva del cerebro, se manifiesta por la desorientación y perdida de memoria. Fue descrita en 1906, por Alois Alzheimer. Anatomopatológicamente, se caracteriza por la aparición de placas seniles conformadas por la acumulación de la molécula amieloide, producto de la APP. Están implicados los cromosomas 1, 14, 19 y 21. El cromosoma 19, sintetiza la proteína activadora APOE, responsable del inicio de la enfermedad. Se han evidenciado anomalías inmunológicas debido a que la molécula amieloide no suele encontrarse en los vertebrados, por lo tanto éstos carecen de enzimas necesarias para degradarla; ello podría explicar la progresiva acumulación de amieloide; motivo por el cual las células de la microglía se activan pero no responden inmunológicamente. | es_CO |
dc.language.iso | es | es_CO |
dc.publisher | Universidad de La Sabana | |
dc.source | Universidad de la Sabana | |
dc.source | Intellectum Repositorio Universidad de la Sabana | |
dc.subject | Enfermedad de Alzheimer | es_CO |
dc.subject | Enfermedades del sistema nervioso | es_CO |
dc.title | Alzheimer: Una mirada neurofisiológica y patológica de la enfermedad. ¿Dónde se origina la enfermedad? | es_CO |
dc.type | bachelorThesis | |
dc.publisher.program | Psicología | |
dc.publisher.department | Facultad de Psicología | |
dc.identifier.local | 88334 | |
dc.identifier.local | TE04585 | |
dc.type.local | Tesis de pregrado | |
dc.type.hasVersion | publishedVersion | |
dc.rights.accessRights | openAccess | |
dc.creator.degree | Psicólogo | |